One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Application of Deep Learning Models to Improve Ulcerative Colitis Endoscopic Disease Activity Scoring Under Multiple Scoring Systems
Michael F Byrne, Remo Panaccione, James E East, Marietta Iacucci, Nasim Parsa, Rakesh Kalapala, Duvvur N Reddy, Hardik Ramesh Rughwani, Aniruddha P Singh, Sameer K Berry, Ryan Monsurate, Florian Soudan, Greta Laage, Enrico D Cremonese, Ludovic St-Denis, Paul Lemaître, Shima Nikfal, Jerome Asselin, Milagros L Henkel, Simon P Travis
doi : 10.1093/ecco-jcc/jjac152
Journal of Crohn's and Colitis, Volume 17, Issue 4, April 2023, Pages 463–471
Lack of clinical validation and inter-observer variability are two limitations of endoscopic assessment and scoring of disease severity in patients with ulcerative colitis [UC]. We developed a deep learning [DL] model to improve, accelerate and automate UC detection, and predict the Mayo Endoscopic Subscore [MES] and the Ulcerative Colitis Endoscopic Index of Severity [UCEIS].
Pneumocystis jirovecii Pneumonia in Patients with Inflammatory Bowel Disease–a Case Series
Sophie Vieujean, Annick Moens, Deborah Hassid, Katja Rothfuss, Edoardo Vincenzo Savarino, Stephan R Vavricka, Catherine Reenaers, Bent Ascanius Jacobsen, Matthieu Allez, Marc Ferrante, Jean-Francois Rahier
doi : 10.1093/ecco-jcc/jjac153
Journal of Crohn's and Colitis, Volume 17, Issue 4, April 2023, Pages 472–479
Pneumocystis jirovecii pneumonia [PJP] is a very rare, potentially life-threatening pulmonary fungal infection that occurs in immunocompromised individuals including patients with inflammatory bowel disease [IBD]. Our aim was to describe immunosuppressive treatment exposure as well as the outcome in IBD patients with PJP.
A Phase IB/IIA Study of Allogeneic, Bone Marrow-derived, Mesenchymal Stem Cells for the Treatment of Refractory Ileal-anal Anastomosis and Peripouch Fistulas in the Setting of Crohn’s Disease of the Pouch
Amy L Lightner, Jane Reese, Justin Ream, Douglas Nachand, Xue Jia, Ana Otero Pineiro, Neda Dadgar, Scott Steele, Tracy Hull
doi : 10.1093/ecco-jcc/jjac172
Journal of Crohn's and Colitis, Volume 17, Issue 4, April 2023, Pages 480–488
Mesenchymal stem cells [MSCs] have been used for the treatment of perianal Crohn’s fistulising disease by direction injection. No studies to date have included patients with an ileal pouch-anal anastomosis [IPAA] in situ.
Post-inflammatory Polyp Burden as a Prognostic Marker of Disease-outcome in Patients with Inflammatory Bowel Disease
Pierre Ellul, John Schembri, Andrea Vella Baldacchino, Tamas Molnár, Tamas Resal, Mariangela Allocca, Federica Furfaro, Arianna Dal Buono, Angeliki Theodoropoulou, Maria Fragaki, Emmanouela Tsoukali, Gerassimos J Mantzaris, Frank M Phillips, Shellie Radford, Gordon Moran, Haidee Gonzalez, Shaji Sebastian, Fotios Fousekis, Dimitrios Christodoulou, Ifat Snir, Zlata Lerner, Henit Yanai, Georgios Michalopoulos, Julia Tua, Liberato Camilleri, Kostas Papamichael, Konstantinos Karmiris, Konstantinos Katsanos
doi : 10.1093/ecco-jcc/jjac169
Journal of Crohn's and Colitis, Volume 17, Issue 4, April 2023, Pages 489–496
Post-inflammatory polyps [PIPs] are considered as indicators of previous episodes of severe inflammation and mucosal ulceration. Inflammatory bowel disease [IBD], namely Crohn’s disease [CD] and ulcerative colitis [UC], exhibit a perpetuating, relapsing and remitting pattern, and PIPs are a frequent sequela of chronicity.
Mortality in Patients with Inflammatory Bowel Disease: Results from 30 Years of Follow-up in a Norwegian Inception Cohort (the IBSEN study)
Benoit Follin-Arbelet, Milada Cvancarova Småstuen, Øistein Hovde, Lars-Petter Jelsness-Jørgensen, Bjørn Moum
doi : 10.1093/ecco-jcc/jjac156
ournal of Crohn's and Colitis, Volume 17, Issue 4, April 2023, Pages 497–503
Patients with longstanding inflammatory bowel disease [IBD] may be at an increased risk of death compared to the general population, especially elderly patients.
Multicentre Real-world Experience of Upadacitinib in the Treatment of Crohn’s Disease
Rishika Chugh, Manuel B Braga-Neto, Thomas W Fredrick, Guilherme P Ramos, Jonathan Terdiman, Najwa El-Nachef, Edward V Loftus, Uma Mahadevan, Sunanda V Kane
doi : 10.1093/ecco-jcc/jjac157
Journal of Crohn's and Colitis, Volume 17, Issue 4, April 2023, Pages 504–512
Upadacitinib is a selective Janus kinase inhibitor approved for the management of ulcerative colitis and is under evaluation for the management of Crohn’s disease [CD] in Phase 3 clinical trials.
Disease Activity and Health-related Quality of Life Relationships with Work Productivity in Patients with Ulcerative Colitis in OCTAVE Induction 1 and 2 and OCTAVE Sustain
Laura Targownik, Marla C Dubinsky, Flavio Steinwurz, Andrew G Bushmakin, Joseph C Cappelleri, Elaine Tai, Sean Gardiner, Peter Hur, Julian Panés
doi : 10.1093/ecco-jcc/jjac161
Journal of Crohn's and Colitis, Volume 17, Issue 4, April 2023, Pages 513–523
Tofacitinib is an oral small molecule Janus kinase inhibitor for the treatment of ulcerative colitis [UC]. We evaluated the relationship between Mayo/Inflammatory Bowel Disease Questionnaire [IBDQ] scores and Work Productivity and Activity Impairment-UC [WPAI-UC] components in patients with UC.
Increased Risk of Cancer and Mortality in a Large French Population-Based Paediatric-Onset Inflammatory Bowel Disease Retrospective Cohort
Claire Dupont-Lucas, Ariane Leroyer, Delphine Ley, Claire Spyckerelle, Valérie Bertrand, Dominique Turck, Guillaume Savoye, Vincent Maunoury, Nathalie Guillon, Mathurin Fumery, Hélène Sarter, Corinne Gower-Rousseau, EPIMAD Study Group
doi : 10.1093/ecco-jcc/jjac166
Journal of Crohn's and Colitis, Volume 17, Issue 4, April 2023, Pages 524–534
Paediatric-onset IBD [pIBD] is associated with an increased risk of cancer and mortality in adulthood. The aims of this study were to measure the incidence of cancer and mortality in patients with pIBD and identify factors associated with mortality and cancer.
Intake of Ultra-processed Foods Is Associated with an Increased Risk of Crohn’s Disease: A Cross-sectional and Prospective Analysis of 187 154 Participants in the UK Biobank
Jie Chen, Judith Wellens, Rahul Kalla, Tian Fu, Minzi Deng, Han Zhang, Shuai Yuan, Xiaoyan Wang, Evropi Theodoratou, Xue Li, Jack Satsangi
doi : 10.1093/ecco-jcc/jjac167
Journal of Crohn's and Colitis, Volume 17, Issue 4, April 2023, Pages 535–552
Ultra-processed food [UPF] consumption has been linked to globally increasing incidence and prevalence of chronic diseases, including inflammatory bowel diseases [IBD]. We aimed to investigate the association between UPF consumption and IBD incidence, prevalence, and IBD-relevant outcomes.
The Oral Microbiome in Treatment-Naïve Paediatric IBD Patients Exhibits Dysbiosis Related to Disease Severity that Resolves Following Therapy
Khalid Elmaghrawy, Paddy Fleming, Kirsten Fitzgerald, Sarah Cooper, Anna Dominik, Séamus Hussey, Gary P Moran
doi : 10.1093/ecco-jcc/jjac155
Journal of Crohn's and Colitis, Volume 17, Issue 4, April 2023, Pages 553–564
There is a limited literature describing the oral microbiome and its diagnostic potential in paediatric inflammatory bowel disease [IBD].
Long-Term Use of Proton Pump Inhibitors Disrupts Intestinal Tight Junction Barrier and Exaggerates Experimental Colitis
Meghali Nighot, Pei-Luan Liao, Nathan Morris, Dennis McCarthy, Viszwapriya Dharmaprakash, Inam Ullah Khan, Shannon Dalessio, Kushal Saha, Ashwinkumar Subramaniam Ganapathy, Alexandra Wang, Wei Ding, Gregory Yochum, Walter Koltun, Prashant Nighot, Thomas Ma
doi : 10.1093/ecco-jcc/jjac168
Journal of Crohn's and Colitis, Volume 17, Issue 4, April 2023, Pages 565–579
Proton pump inhibitors [PPIs] are widely used to treat a number of gastro-oesophageal disorders. PPI-induced elevation in intragastric pH may alter gastrointestinal physiology.
Association of Neutrophil Extracellular Traps with Fistula Healing in Patients with Complex Perianal Fistulizing Crohn’s Disease
Dongxing Cao, Keyu Qian, Ying Zhao, Jie Hong, Haoyan Chen, Xiaohui Wang, Nailin Yang, Cheng Zhang, Jingkai Cao, Keyu Jia, Guangyu Wu, Mingming Zhu, Jun Shen, Ye Zhang, Zhe Cui, Zheng Wang
doi : 10.1093/ecco-jcc/jjac171
Journal of Crohn's and Colitis, Volume 17, Issue 4, April 2023, Pages 580–592
Perianal fistulizing Crohn’s disease [pfCD] is a disabling phenotype of Crohn’s disease [CD] with suboptimal outcomes. We assessed neutrophil extracellular traps [NETs] in perianal fistulas and implicated their roles in pfCD healing.
circSMAD4 Promotes Experimental Colitis and Impairs Intestinal Barrier Functions by Targeting Janus Kinase 2 Through Sponging miR-135a-5p
Jie Zhao, Zhiliang Lin, Pu Ying, Zhibin Zhao, Haojun Yang, Jun Qian, Yu Gong, Yan Zhou, Yi Dai, Yuwen Jiao, Weiming Zhu, Honggang Wang, Liming Tang
doi : 10.1093/ecco-jcc/jjac154
Journal of Crohn's and Colitis, Volume 17, Issue 4, April 2023, Pages 593–613
Numerous studies have explored the association between circular RNAs [circRNAs] and Crohn’s disease [CD]. However, the pathological role, biological functions, and molecular mechanisms of circRNAs in CD have not been fully elucidated.
Fertility and Assisted Reproductive Technologies Outcomes of Women with Non-surgically Managed Inflammatory Bowel Diseases: A Systematic Review
Sophie Vieujean, Michel De Vos, Kristine Paridaens, Gaurang S Daftary, Silvio Danese, Laurent Peyrin-Biroulet
doi : 10.1093/ecco-jcc/jjac170
Journal of Crohn's and Colitis, Volume 17, Issue 4, April 2023, Pages 614–632
In view of their frequent onset during childbearing years, the impact of inflammatory bowel diseases [IBD] on reproductive health is of important concern to young women and to the IBD physician. This study aims to assess the fertility and assisted reproductive technologies outcomes in non-surgically treated IBD females.
A Systematic Review on the Interest of Drug-tolerant Assay in the Monitoring of Inflammatory Bowel Disease
Mathilde Barrau, Manon Duprat, Pauline Veyrard, Quentin Tournier, Nicolas Williet, Jean Marc Phelip, Louis Waeckel, Adam S Cheifetz, Konstantinos Papamichael, Xavier Roblin, Stephane Paul
doi : 10.1093/ecco-jcc/jjac164
Journal of Crohn's and Colitis, Volume 17, Issue 4, April 2023, Pages 633–643
Many patients with inflammatory bowel disease [IBD] are treated with anti-tumour necrosis factor [TNF] therapies, of which infliximab [IFX] is most commonly used. Loss of response [LOR] to anti-TNF therapy due to immunogenic failure accounts for 20% of subsequent medical intervention and is defined, using a drug-sensitive assay, as low or undetectable concentration of drug with high titres of anti-drug antibodies [ADAb].
Placebo Response Rates in Randomized Controlled Trials for Perianal Crohn’s Disease: A Systematic Review and Meta-Analysis
Tanmay Sharma, Christopher Ma, Rocio Sedano, Jurij Hanzel, Cassandra McDonald, Malcolm Hogan, Gursimran S Kochhar, Neeraj Narula, Laurent Peyrin-Biroulet, Silvio Danese, John K MacDonald, Vipul Jairath
doi : 10.1093/ecco-jcc/jjac160
Journal of Crohn's and Colitis, Volume 17, Issue 4, April 2023, Pages 644–658
Perianal fistulizing disease is a common complication of Crohn’s disease [CD], for which new therapies are urgently needed. To assist the design of clinical trials for novel therapeutics, we conducted a systematic review and meta-analysis of randomised controlled trials [RCTs] to quantify placebo rates and identify factors influencing them in perianal CD [pCD].
Corrigendum to: Long-term Oncological Outcome of Segmental Versus Extended Colectomy for Colorectal Cancer in Crohn’s Disease: Results from an International Multicentre Study
doi : 10.1093/ecco-jcc/jjac158
Journal of Crohn's and Colitis, Volume 17, Issue 4, April 2023, Page 659
Corrigendum: The Oral Microbiome in Treatment-Naïve Paediatric IBD Patients Exhibits Dysbiosis Related to Disease Severity that Resolves Following Therapy
doi : 10.1093/ecco-jcc/jjad003
Erratum to: Post-inflammatory Polyp Burden as a Prognostic Marker of Disease-outcome in Patients with Inflammatory Bowel Disease
doi : 10.1093/ecco-jcc/jjad028
Journal of Crohn's and Colitis, Volume 17, Issue 4, April 2023, Page 661
